• SoftOx disclosed in vitro data showing its SoftOx Inhalation Solution cut viable Yersinia pestis by more than 7 log10 in one minute.
• Findings support development of SIS as a non-antibiotic inhaled countermeasure for plague, with no human efficacy established.
• Phase 1 biodefense study SIS-02 is ongoing to assess safety, tolerability, and pulmonary exposure in healthy volunteers.
• Separately, a Phase 2a proof-of-concept trial is testing SIS as an inhaled anti-infective for chronic airway infections.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SoftOx Solutions AS published the original content used to generate this news brief via NewsWeb, the disclosure sustem operated by Euronext Oslo (Ref. ID: 202610080814OSLOBORSNEWS__EN_DB654558BCC375084B180B2024595A6), on October 08, 2026, and is solely responsible for the information contained therein.